CordenPharma has completed a new highly potent active pharmaceutical ingredient (API) laboratory in its Boulder, CO, facility.
 
CordenPharma Colorado has extensive experience and capabilities in the development and manufacturing of highly potent APIs from clinical to commercial scale.
 
“Our new laboratory in Colorado is part of a development capacity expansion to address the strong market demand,” said Jason Bertola, director of CordenPharma’s global highly potent and oncology platform. “This additional capacity benefits customers by expediting the onboarding of new projects.”
 
The new laboratory is capable of handling highly potent compounds with an OEL as low as 1ng/m3, and is already available to customers.